Attana's presentation from Stora Aktiedagen is now available on Aktiespararna’s YouTube channel

On Tuesday, November 29 at Attana attended Stora Aktiedagen where Teodor, CEO of Attana, held a 20-minute company presentation followed by a 10-minute Q&A session.

The main purpose of the presentation was to present Attana´s two business areas, Life Science and Diagnostics, and the most recent progress made in each area. Information regarding Attana´s upcoming rights issue with a subscription period running December 14–29 was also presented.

The presentation can be viewed by following this link:

Attana – Stora Aktiedagen 2022

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com